By Paige Minemyer
Out-of-network costs for COVID-19 testing far outpace the costs for in-network tests, according to a new report from America's Health Insurance Plans.
read more
By Conor Hale
The FDA has given its green light to a new coronavirus test from Abbott, which will be sold for $5 and fits entirely on a device about the size of a credit card.
read more
By Paige Minemyer
As many as 12 million people have lost access to employer-sponsored coverage as a result of COVID-19, a new analysis shows.
read more
By Amirah Al Idrus
As the world scrambles to develop diagnostics, treatments and vaccines for COVID-19, one big question looms: How will we face the next pandemic? Johnson & Johnson and the U.S. Biomedical Advanced Research and Development Authority are teaming up once again to answer that.
read more
By Eric Sagonowsky, Angus Liu, Kyle Blankenship, Conor Hale, Fraiser Kansteiner
The EU made a $396 million downpayment for at least 300 million AstraZeneca vaccines. Pfizer's shot could snare approval by October, one analyst thinks. J&J teamed up with BARDA to support startups working on COVID-19. Regeneron will add 400 jobs at its Irish plant; plus, Vaccitech snared funding for a new COVID-19 shot.
read more
By Healthcare Staff
Follow along with the latest COVID-19 news straight from the Fierce Healthcare team.
read more
By Tina Reed
Drops in hospital revenue—largely due to cancellations of elective surgeries in the months after the start of the COVID-19 pandemic—are expected to have the greatest impact across the industry over the next year, according to a new survey of healthcare leaders.
read more
By Kyle Blankenship
With a suite of COVID-19 vaccines and therapeutics on their way to market, the federal government has been working to secure enough manufacturing capacity to meet demand. Now, the U.S. Army will pay big money to a Florida CDMO to snare millions of potential doses.
read more
By Nick Paul Taylor
Vaccitech has received U.K. government funding for a COVID-19 vaccine that it thinks can improve on first-generation prospects such as the AstraZeneca jab it helped develop.
read more
By Robert King
An increase in UPMC's insurance business helped the health system overcome declines in patient volume in the first half of the year due to COVID-19.
read more
By Kyle Blankenship
Regeneron and Swiss drugmaker Roche made waves earlier this month with a gargantuan manufacturing pact to triple production of a COVID-19 antibody candidate. But those big plans put a crunch on Regeneron's ability to churn out its regular meds, and now it's expanding at an Irish site to keep up.
read more
